Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8543)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 15, 2023 (publication date) through Sep 12, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8470/full/v15/i1/1.htm |
| Number | Citing Articles |
| 1 |
Changlong Hou, Baizhu Xiong, Lei Zhou, Yipeng Fei, Changgao Shi, Xianhai Zhu, Tao Xie, Yulin Wu. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12144-6
|
| 2 |
Ming-Zhi Hao, Hai-Lan Lin, Yu-Bin Hu, Qi-Zhong Chen, Zhang-Xian Chen, Lin-Bin Qiu, Duan-Yu Lin, Hui Zhang, De-Chun Zheng, Zhu-Ting Fang, Jing-Feng Liu. Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma: A case report. World Journal of Gastrointestinal Oncology 2025; 17(3): 100861 doi: 10.4251/wjgo.v17.i3.100861
|
| 3 |
Beichuan Pang, Bangyou Zuo, Liang Huang, Xinyu You, Tao Liu, Jianjie Hao, Chengxiang Yuan, Chong Yang, Wan Yee Lau, Yu Zhang. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. International Immunopharmacology 2024; 137: 112492 doi: 10.1016/j.intimp.2024.112492
|
| 4 |
Yutao Chen, Desheng Chen, Zhixing Liang, Haoyuan Yu, Haobin Sun, Yongwei Hu, Peng Jiang, Mingshen Zhang, Linsen Ye, Hua Li. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies. Cancer Drug Resistance 2025; doi: 10.20517/cdr.2025.120
|
| 5 |
Junning Liu, Guangnian Zhang, Linfeng Yang, Duan Yan, Jiahui Yu, Song Wei, Jijiang Li, Pengsheng Yi. Salvage liver transplantation versus curative treatment for patients with recurrent hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology 2024; 50(7): 108427 doi: 10.1016/j.ejso.2024.108427
|
| 6 |
Yubo Jiang, Xiaofeng Dong, Yingying Zhang, Feiyan Su, Lei Zhao, Xuetao Shi, Jingtao Zhong. Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01698-9
|
| 7 |
Mingqiang Liu. Effect of regorafenib combined with immunotherapy and arterial chemoembolization on the survival of patients with advanced hepatocellular carcinoma: a retrospective study. American Journal of Translational Research 2025; 17(3): 1962 doi: 10.62347/BXYO6569
|